Prostanoids for critical limb ischaemia

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 1, 2018, Pages

  Vietto, Valeria ^a,b   Franco, Juan V A ^b   Saenz, Victoria ^c   Cytryn, Denise ^a   Chas, Jose ^a   Ciapponi, Agustín ^d  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b Instituto Universitario del Hospital Italianode Buenos Aires and   (Argentina)

^c Unidad Asistencial Dr César Milstein   (Argentina)

^d INSTITUTE FOR CLINICAL EFFECTIVENESS AND HEALTH POLICY   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPROSTADIL ALFADEX; ANALGESIC AGENT; BERAPROST; CILOSTAZOL; CIPROSTENE; ECRAPROST; ILOPROST; ISOCARBACYCLIN METHYL ESTER; NAFTIDROFURYL; PENTOXIFYLLINE; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN E1; PROSTANOID; TAPROSTENE; INOSITOL NICOTINATE; NICOTINIC ACID DERIVATIVE; PROSTAGLANDIN; VASODILATOR AGENT;

AMPUTATION; ANALGESIA; ANKLE BRACHIAL INDEX; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CRITICAL LIMB ISCHEMIA; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HEADACHE; HUMAN; HYPOTENSION; INJECTION PAIN; INJECTION SITE IRRITATION; LIMB BLOOD VESSEL; LIMB PAIN; LOW DRUG DOSE; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULCER HEALING; UNSPECIFIED SIDE EFFECT; VOMITING; ISCHEMIA; LEG; LEG ULCER; META ANALYSIS; MORTALITY; PERIPHERAL VASCULAR DISEASE; STATISTICS AND NUMERICAL DATA; SURGERY; VASCULARIZATION;

ALPROSTADIL; AMPUTATION; EPOPROSTENOL; HUMANS; ILOPROST; ISCHEMIA; LEG; LEG ULCER; NAFRONYL; NICOTINIC ACIDS; PENTOXIFYLLINE; PERIPHERAL VASCULAR DISEASES; PROSTAGLANDINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASODILATOR AGENTS;

EID: 85041468353     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006544.pub3     Document Type: Article

References (110)

1. Altstaedt HO, Berzewski B, Breddin HK, Brockhaus W, Bruhn HD, Cachovan M, et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids 1993;49(2):573-8
2. Balzer K, Bechara G, Bisler H, Clevert HD, Diehm C, Heisig G, et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. International Angiology 1991;10(4):229-32
3. Bandiera G, Di Crisci D, Camilli S. Analysis of side effects of prostanoid-based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica 1995;5(2):249-60
4. Belch JJ, McKay A, McArdle B, Leiberman P, Pollock JG, Lowe GD, et al. Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial. Lancet 1983;1(8320): 315-7
5. Belch JJ, Ray S, Rajput-Ray M, Engeset J, Fagrell B, Lepantalo M, et al. The Scottish-Finnish-Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology 2011;30(2):150-5. PUBMED: 21427652]
6. Böhme H, Brulisauer M, Hartel U, Bollinger A. Peripheral arterial occlusive disease stage III and IV. Medizinische Welt 1989;40(51-52):1501-3
7. Böhme H, Hartel U, Walter H. Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt 1994;45(5):209-13
8. Brass 2006 (published and unpublished data) Brass EP, Anthony R, Dormandy J, Hiatt WR, Jiao J, Nakanishi A, et al. (Circulase investigators). Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. Journal of Vascular Surgery 2006; 43(4):752-9
9. Brock FE, Abri O, Baitsch G, Bechara G, Beck K, Corovic D, et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo-controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift 1990;120(40):1477-82
10. Castagno PL, Molfetta L, Merlo M, Barile G, Violato F, Buzzacchino A, et al. Prospects of prostanoid therapy. Preliminary results. Minerva Cardioangiologica 2000; Vol. 48, issue 1-2:9-18. CN-00278141]
11. Cronenwett JL, Zelenock GB, Whitehouse WM Jr, Lindenauer SM, Graham LM, Stanley JC. Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructable peripheral arterial occlusive disease. Surgery 1986;100(2):369-75
12. Diehm C, Hubsch-Muller C, Stammler F. Intravenous prostaglandin E1 therapy in patients with stage III peripheral arterial disease-a double-blind placebo controlled study. Prostaglandin E1 Wirkungen und Therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988: 133-43
13. Diehm C, Stammler F, Hubsch-Muller C, Eckstein HH, Simini B. Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD)-a preliminary report on a placebo-controlled double-blind study. Vasa Supplementum 1987;17:52-6
14. Diehm C, Stammler F, Hubsch C, Wilhelm C, Eckstein HH. Treatment of rest pain in peripheral arterial occlusive disease (PVVK) with intravenous prostaglandin infusion. Vasa Supplementum 1987;20:204-5
15. Diehm C, Abri O, Baitsch G, Bechara G, Beck K, Breddin HK, et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo-controlled multicentre study. Deutsche Medizinische Wochenschrift 1989;114(20):783-8
16. Dormandy JA, U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double-blind placebo controlled study. European Journal of Vascular Surgery 1991;5(5): 511-6
17. Dormandy J, Belcher G, Boccalon H, Braga A, Breddin K, Catalano M, et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery 1996;83(4):558-9
18. Dormandy JA. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery 2000;20(4):358-62
19. Dormandy JA. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery 2000;20(4):358-62
20. Esato K, Yasuda K, Abe T, Hoshino S, Ishimaru S, Hori G, et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres [TTC-909 Alprostadil Rinsho Iyaku 1995; Vol. 11, issue 10:2111-41. CN-00543666]
21. Guilmot J-L, Diot E, French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation 1991;3(5):351-9
22. Hossmann V, Auel H, Rucker W, Schror K. Long-term infusion of epoprostenol (prostacyclin) in patients with occlusive arteriopathy stage III-IV. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin 1983;89:540-4
23. Jogestrand T, Olsson AG. The effect of intravenous prostaglandin E1 on ischaemic pain and on leg blood-flow in subjects with peripheral artery disease: a double-blind controlled study. Clinical Physiology (Oxford, England) 1985; Vol. 5, issue 6:495-502. CN-00041639]
24. Karnik R, Valentin A, Slany J. A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf 1986;18(12):644-7
25. Linet OI, Eckert SM, Huang DC. The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology 1991;31(1):81-7. NCT00596752 (unpublished data only) Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. 2005-001970-29 (EudraCT Number); SP0777 (Sponsor ID)]
26. Negus D, Irving JD, Friedgood A. Intra-arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino) 1987;28(2):196-9
27. Norgren L, Alwmark A, Angqvist KA, Hedberg B, Bergqvist D, Takolander R, et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery 1990;4(5): 463-7
28. Reisin L, Marmor A, Rabinowitz B, Bernink PJ, Caspi A, Ruzyllo W, et al. Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. American Journal of Therapeutics 1997; Vol. 4, issue 11-12:365-74. CN-00265681]
29. Sakaguchi S. Prostaglandin E1 intra-arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology 1084;3:39-41
30. Schellong S, Altmann E, von Bilderling P, Rudofsky G, Waldhausen P, Rogatti W. Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross-over study in patients with critical limb ischemia. Prostaglandins Leukotrienes and Essential Fatty Acids 2004;70 (6):503-9
31. Rhodes RS, Heard SE. Detrimental effect of high-dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery 1983; Vol. 93, issue 6:839-42. CN-00177644]
32. Schuler JJ, Flanigan DP, Holcroft JW, Ursprung JJ, Mohrland JS, Pyke J. Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double-blind, multicenter clinical trial. Journal of Vascular Surgery 1984;1(1):160-70. PUBMED: 6384558]
33. Stiegler H, Diehm C, Grom E, Martin M, Morl H, Rudofsky G, et al. Placebo controlled, double-blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease [Placebokontrollierte, doppelblinde Studie zurWirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV]. VASA 1992; 35 (Suppl):164-6
34. Telles GS, Campbell WB, Wood RFM, Collin J, Baird RN, Morris PJ, et al. Prostaglandin E1 in severe lower limb ischaemia: a double-blind controlled trial. British Journal of Surgery 1984;71(7):506-8
35. Trubestein G, Diehm C, Gruss JD, Horsch S. Prostaglandin E1 in chronic arterial disease-a multicenter study. VASA Supplementum 1987;17:39-43. PUBMED: 3470965]
36. Trubestein G, Ludwig M, Diehm C, Gruss JD, Horsch S. Prostaglandin E1 in stage III and IV arterial occlusive disease: results of a multi-center trial. Deutsche Medizinische Wochenschrift 1987;112(24):955-9
37. Trubestein G, Von Bary S, Breddin K, Diehm C, Gruss JD, Heinrich H, et al. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease-a controlled randomised multicenter study. VASA Supplementum 1989;28:44-9
38. Arosio E, Sardina M, Prior M, De Marchi S, Zannoni M, Bianchini C. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III. European Review for Medical and Pharmacological Sciences 1998;2(2):53-9
39. Beischer W, Dembski JC, Gruss JD, Hofgartner F, Horsch A, Horsch S, et al. Low-dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. DAWID Study Group. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases 1998;27(1):15-9
40. Bertele V. Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1. Annals of Internal Medicine 1999;130(5):412-21
41. Breuer C, Abri O. Prostacyclin (iloprost) as an adjuvant in local surgical therapy of stage IV arterial occlusive disease-is quantification of the therapeutic effect possible with tcPO2 measurements?. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases 1995;24(1):62-71
42. Ceriello A, SardinaM, Motz E, Lizzio S, Tuniz D, Bianchini C. Effects of iloprost, either administered for 1 week or 4 weeks, on systemic hemodynamics, peripheral blood flow, and exercise tolerance in patients with peripheral occlusive arterial disease at Leriche-Fontaine stage III. International Journal of Angiology 1998;7(1):28-33
43. Di Paolo N, Bocci V, Salvo DP, Palasciano G, Biagioli M, Meini S, et al. Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. International Journal of Artificial Organs 2005;28(10):1039-50
44. Esato K, Yasuda K, Abe T, Hoshino S, Ishimaru S, Hori G, et al. Clinical study of TTC-909 (Prostacyclin derivative, clinprost incorporated in lipid microspheres) in patients with peripheral arterial occlusive disease: establishment of optimal dose in multi-center double-blind comparative study. Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines) 1995; Vol. 11, issue 10:2083-110. CN-00543531]
45. Esato K, Yasuda K, Abe T, Hoshino S, Ishimaru S, Hori G, et al. Clinical study of TTC-909 (Prostacyclin derivative, clinprost incorporated in lipid microspheres) in patients with peripheral arterial occlusive disease: establishment of optimal dose in multi-center double-blind comparative study. Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines) 1997; Vol. 13, issue 21:5595-622. CN-00543608]
46. Feng K, Tan JF, Chen Y. Treatment of lower extremity diabetic atherosclerotic obliterans with shuxuetong injection. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese Journal of Integrated Traditional and Western Medicine/Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban 2009; Vol. 29, issue 3:255-7. CN-00749881] Fonseca 1991 (published and unpublished data) Fonseca V, Dandona P, Belcher G. Treatment of ischaemic ulceration or rest pain with intravenous Iloprost: a doubleblind placebo controlled study. Diabetes 40 1991;Suppl 1: 522A
47. Guan H, Wang Y, Zhang B, Ye W, Fu W, Liang W, et al. Comparison of beraprost and ticlopidine in Chinese patients with chronic peripheral arterial occlusion: a multicenter, single blind, randomized, controlled study. Current Therapeutic Research 2003;64(7):488-503
48. Heidrich H, Brodel C, Meuche C, Hellman M, Ranft J. Controlled long-term blood pressure measurement with intravenous prostaglandin E1 infusion [Kontrollierte blutdrucklangzeitmessung unter intravenoser prostaglandin-E1-infusion]. VASA 1991;20(1):13-6
49. Menzoian J. Alprostadil in the treatment of patients with severe peripheral arterial occlusive disease (PAOD) not amenable to surgery: results of a randomized, placebocontrolled multicenter study. International Angiology 1995; 14(Suppl 1):104
50. Mingardi R, Rumor F, Strazzabosco M, et al. Medical therapy in diabetic angiopathy with inoperable critical limb ischemia (CLI)-a randomized, between-patients study to compare the effects of iloprost (I) vs pentoxyfilline (P). Thrombosis and Haemostasis 1993;69(6):1243
51. Efficacy/safety of ecraprost in lipid emulsion for treatment of critical leg ischemia due to peripheral arterial disease [A double-blind, randomized, placebo-controlled study to assess the efficacy and safety of CirculaseTM for the treatment of critical leg ischemia]. clinicaltrials.gov/ct2/show/NCT00059644. Date first received: 29 April 2003
52. Nizankowski R, Królikowski W, Bielatowicz J, Szczeklik A. Prostacyclin for ischemic ulcers in peripheral arterial disease. A random assignment, placebo controlled study. Thrombosis Research 1985; Vol. 37, issue 1:21-8. CN-00037548]
53. Ohtake T, Sato M, Nakazawa R, Kondoh M, Kobayashi S. Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study. Nephrology Dialysis Transplantation Plus 2010;3: iii487
54. Ohtake T, Sato M, Nakazawa R, Kondoh M, Miyaji T, Moriya H, et al. Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis and Dialysis 2014; Vol. 18, issue 1:1-8. [DOI: 10.1111/1744-9987.12051; CN-00978202
55. Petronella P, Freda F, Nunziata L, Antropoli M, Manganiello A, Cutolo PP, et al. Prostaglandin E1 versus lumbar sympathectomy in the treatment of peripheral arterial occlusive disease: randomised study of 86 patients. Nutrition, Metabolism, and Cardiovascular Diseases 2004;14 (4):186-92
56. Sakaguchi-Shukichi. Evaluation of the efficacy of beraprost sodium (PGI2 analogue) in chronic arterial occlusion: a double-blind comparative study with ticlopidine hydrochloride. Rinsho to Kenkyu 1990; Vol. 67:575-84. CN-00740416]
57. Schwarz E, Ratti R, Durante F, Buskermolen M, Brighenti G. Iloprost vs nitrates and aspirin in the treatment of geriatric patients suffering of peripheral arterial obliterative disease. International Angiology 1995;14(Suppl 1):201
58. SertM, Soydas B, Aikimbaev K, Tetiker T. Effects of iloprost (a prostacyclin analogue) on the endothelial dysfunction and foot ulcers in diabetic patients with peripheral arterial disease. International Journal of Diabetes and Metabolism 2008; Vol. 16, issue 1:7-11. CN-00754583]
59. Weiss T, Griesshaber J, RogattiW, Kistner O, Hsu E, Jansen T, et al. Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities. VASA Supplementum 1991; Vol. 33:341-2. CN-00081779]
60. Ylitalo P, Kaukinen S, Reinikainen P, Salenius JP, Vapaatalo H. A randomized, double-blind, crossover comparison of iloprost with dextran in patients with peripheral arterial occlusive disease. International Journal of Clinical Pharmacology, Therapy, and Toxicology 1990; Vol. 28, issue 5:197-204. CN-00068745]
61. Abu Dabrh AM, Steffen MW, Undavalli C, Asi N, Wang Z, Elamin MB, et al. The natural history of untreated severe or critical limb ischemia. Journal of Vascular Surgery 2015; 62(6):1642-51.e3. [PUBMED: 26391460]
62. Albers M, Fratezi AC, De Luccia N. Assessment of quality of life of patients with severe ischemia as a result of infrainguinal arterial occlusive disease. Journal of Vascular Surgery 1992;16(1):54-9
63. Anonymous. Second European Consensus Document on chronic critical leg ischemia. Circulation 1991;84(4 Suppl): 1-26
64. Aquino R, Johnnides C, Makaroun M, Whittle JC, Muluk VS, Kelley ME, et al. Natural history of claudication: longterm serial follow-up study of 1244 claudicants. Journal of Vascular Surgery 2001;34(6):962-70. [PUBMED: 11743546]
65. Becker F, Robert-Ebadi H, Ricco JB, Setacci C, Cao P, de Donato G, et al. Chapter I: Definitions, epidemiology, clinical presentation and prognosis. European Journal of Vascular and Endovascular Surgery 2011;42 (Suppl 2): S4-12. [PUBMED: 22172472]
66. Brodszky V, Farkas K, Jarai Z, Landi A, Pecsvarady Z, Baji P, et al. Effectiveness of prostanoids in patients with critical leg ischemia [Prosztanoidok hatasossaga kritikus vegtagischaemiaban.]. Orvosi Hetilap 2011;152(51): 2047-55. [PUBMED: 22130202]
67. Cacione DG, Baptista-Silva JC, Macedo CR. Pharmacological treatment for Buerger's disease. Cochrane Database of Systematic Reviews 2016, Issue 2. [DOI: 10.1002/14651858.CD011033.pub3
68. Creutzig A, Lehmacher W, Elze M. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. Vasa 2004;33(3):137-44
69. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circulation Research 2015;116(9):1509-26. [PUBMED: 25908725]
70. Diehm C, Stammler F, Hubsch-Muller C, Eckstein HH, Simini B. Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD)-a preliminary report on a placebo-controlled double-blind study. Vasa Supplementum 1987;17:52-6
71. Dormandy JA. Prostanoid drug therapy for peripheral arterial occlusive disease-the European experience. Vascular Medicine 1996;1(2):155-8
72. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). Journal of Vascular Surgery 2000;31(1 Pt 2):S1-S296
73. Dua A, Lee CJ. Epidemiology of peripheral arterial disease and critical limb ischemia. Techniques in Vascular and Interventional Radiology 2016;19(2):91-5. [PUBMED: 27423989]
74. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2016;69(11):1465-508. [PUBMED: 27840333]
75. GRADEpro GDT: GRADEpro Guideline Development Tool [Computer program]. Version accessed May 2017. Hamilton (ON): McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from www.gradepro.org
76. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Schünemann HJ. GRADE: what is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed.) 2008;336(7651):995-8. [DOI: 10.1136/bmj.39490.551019.BE
77. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [DOI: 10.1016/j.jclinepi.2010.04.026
78. Hammer A, Steiner S. Gene therapy for therapeutic angiogenesis in peripheral arterial disease-a systematic review and meta-analysis of randomized, controlled trials. VASA Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases 2013;42(5):331-9. [PUBMED: 23989068]
79. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org
80. Higgins JPT, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org
81. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, GreagerMA, Halperin JL, et al. ACC/AHA 2005 Practice guidelines for the management of patients with peripheral arterial disease. Circulation 2006;113(11):463-654
82. Howard DP, Banerjee A, Fairhead JF, Hands L, Silver LE, Rothwell PM. Population-based study of incidence, risk factors, outcome, and prognosis of ischemic peripheral arterial events: implications for prevention. Circulation 2015;132(19):1805-15. [PUBMED: 26350058]
83. Hylton JR, Smith CA, Li CS, Pevec WC. Octogenarians develop infrapopliteal arterial occlusive disease in the absence of traditional risk factors. Annals of Vascular Surgery 2014;28(7):1712-8. [PUBMED: 24858583]
84. The ICAI Group. Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1. Annals of Internal Medicine 1999;130(5): 412-21
85. Jelnes R, Gaardsting O, Hougaard Jensen K, Backgaard N, Tonnesen KH, Schroeder T, et al. Fate in intermittent claudication: outcome and risk factors. British Medical Journal (Clinical Research Ed.) 1986;293(6555):1137-40
86. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001; 24(8):1433-7. [PUBMED: 11473082]
87. Loosemore TM, Chalmers TC, Dormandy JA. A metaanalysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. International Angiology 1994;13(2):133-42
88. Malyar NM, Freisinger E, Meyborg M, Luders F, Furstenberg T, Kroger K, et al. Low rates of revascularization and high in-hospital mortality in patients with ischemic lower limb amputation: morbidity and mortality of ischemic amputation. Angiology 2016;67(9):860-9. [PUBMED: 26764367]
89. Melillo E, Micheletti L, Nuti M, Dell'Omo G, Berchiolli R, Adami D, et al. Long-term clinical outcomes in critical limb ischemia-a retrospective study of 181 patients. European Review for Medical and Pharmacological Sciences 2016;20(3): 502-8. [PUBMED: 26914126]
90. Miao YL, Wu W, Li BW, Fang WW, Liu Y, Li L, et al. Clinical effectiveness of gene therapy on critical limb ischemia: a meta-analysis of 5 randomized controlled clinical trials. Vascular and Endovascular Surgery 2014;48(5-6):372-7. [PUBMED: 24951292]
91. Moazzami K, Moazzami B, Roohi A, Nedjat S, Dolmatova E. Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD008347.pub3
92. Moxey PW, Hofman D, Hinchliffe RJ, Jones K, Thompson MM, Holt PJ. Epidemiological study of lower limb amputation in England between 2003 and 2008. British Journal of Surgery 2010;97(9):1348-53. [PUBMED: 20632310]
93. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). European Journal of Vascular and Endovascular Surgery 2007; 33 (Suppl 1):S1-75. [PUBMED: 17140820]
94. Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. Journal of the American Geriatrics Society 2007;55(4):583-9. [PUBMED: 17397438]
95. Patel MR, Conte MS, Cutlip DE, Dib N, Geraghty P, Gray W, et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). Journal of the American College of Cardiology 2015;65(9): 931-41. [PUBMED: 25744011]
96. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014
97. Robertson L, Andras A. Prostanoids for intermittent claudication. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD000986.pub3
98. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org
99. Sen I, Agarwal S, Tharyan P. Lumbar sympathectomy versus prostanoids for critical limb ischaemia due to non-reconstructable peripheral arterial disease. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD009366
100. Sigvant B, Lundin F, Wahlberg E. The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. European Journal of Vascular and Endovascular Surgery 2016;51(3):395-403. [PUBMED: 26777541]
101. Sprengers RW, Teraa M, Moll FL, deWit GA, van der Graaf Y, Verhaar MC. Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment. Journal of Vascular Surgery 2010;52(4):843-9, 849.e1. [PUBMED: 20598482]
102. Suckow BD, Goodney PP, Cambria RA, Bertges DJ, Eldrup-Jorgensen J, Indes JE, et al. Predicting functional status following amputation after lower extremity bypass. Annals of Vascular Surgery 2012;26(1):67-78. [PUBMED: 22176876]
103. Suckow BD, Goodney PP, Nolan BW, Veeraswamy RK, Gallagher P, Cronenwett JL, et al. Domains that determine quality of life in vascular amputees. Annals of Vascular Surgery 2015;29(4):722-30. [PUBMED: 25725279]
104. Teraa M, Conte MS, Moll FL, Verhaar MC. Critical limb ischemia: current trends and future directions. Journal of the American Heart Association 2016;5(2):e002938
105. Trubestein G, von Bary S, Breddin K, Diehm C, Gruss JD, Heinrich H, et al. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease-a controlled randomised multicenter study. Vasa Supplementum 1989;28:44-9
106. Ubbink DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD004001.pub3
107. Verstraete M. prostaglandins in critical limb ischemia. Vascular Medicine Review 1994;5(2):93-5
108. Vitale V, Monami M, Mannucci E. Prostanoids in patients with peripheral arterial disease: a meta-analysis of placebocontrolled randomized clinical trials. Journal of Diabetes and Its Complications 2016;30(1):161-6. [PUBMED: 26516035]
109. Ruffolo AJ, Romano M, Ciapponi A. Prostanoids for critical limb ischemia. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD006544
110. Ruffolo AJ, Romano M, Ciapponi A. Prostanoids for critical limb ischaemia. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD006544.pub2